2 Poster Session 2

EFFECT OF ITRACONAZOLE ON PK PROFILE OF LEMBOREXANT IN HEALTHY VOLUNTEERS AND APPLICATION OF PBPK MODELING TO DDI SIMULATIONS WITH CYP3A INHIBITORS.
Takashi Ueno, Eisai Co., Ltd.; Bhaskar Rege, Eisai Inc.; Jagadeesh Aluri, Eisai Inc.; Kazutomi Kusano, Eisai Co., Ltd.
THE IMPACT OF LYSOSOMAL SEQUESTRATION ON DESIPRAMINE CELLULAR DISPOSITION AND METABOLIC DRUG-DRUG INTERACTIONS IN RAT AND HUMAN HEPATOCYTES
Ayşe Ufuk, Centre for Applied Pharmacokinetic Research, University of Manchester; Norikazu Matsunaga, Centre for Applied Pharmacokinetic Research, University of Manchester; David Hallifax, Centre for Applied Pharmacokinetic Research, University of Manchester; Aleksandra Galetin, Centre for Applied Pharmacokinetic Research, University of Manchester
Investigating the Effects of Typical Clinical CYP3A Inducers in Humanized PXR-CAR-CYP3A4/7 Animal Models
Jae H. Chang, Genentech; Ruina Li, Genentech; Kirsten Messick, Genentech; Justin Q. Ly, Genentech Inc.
METABOLISM OF PF-04958242: SUBSTRATE CONCENTRATION-DEPENDENT IMPACT OF CYTOCHROME P4503A4 INHIBITORS AS AN EXPLANATION FOR A LACK OF CLINICAL DRUG-DRUG INTERACTION AT VERY LOW SUBSTRATE DOSES
R. Scott Obach, Pfizer Inc.; Angela C Doran, Pfizer Inc., Medicinal Sciences; Christopher L. Shaffer, Pfizer Inc; John Litchfield, Pfizer Inc.
THE USE OF BOVINE SERUM ALBUMIN IN PHENOTYPING EXPERIMENTS BY SUBSTRATE DEPLETION APPROACH TO DETERMINE fm, cyp: APPLICATION TO CYP2B6 SUBSTRATES WITH EMPHASIS ON BUPROPION
Raghava Choudary Palacharla, Suven Life Sciences Ltd; Venkatesham Uthukam, Suven Life Sciences Ltd; Arun Kumar Manoharan, Suven Life Sciences Ltd; Ilayaraja Kalaikadhiban, Suven Life Sciences Ltd.; Rajesh Kumar Boggavarapu, Suven Life Sciences Ltd; Nagasurya Prakash Padala, Suven Life Sciences Ltd; Ramakrishna Nirogi, Suven Life Sciences Ltd
ASSESSING THE OATP1B1- AND OATP1B3-MEDIATED DRUG-DRUG INTERACTION POTENTIAL OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR EVEROLIMUS
Taleah Farasyn, University of Oklahoma Health Sciences Center; Khondoker Alam, University of Oklahoma Health Sciences Center; Alexandra Crowe, University of Oklahoma Health Sciences Center; Sibylle Neuhoff, Simcyp Ltd (a Certara Company); Oliver Hatley, Simcyp Ltd (a Certara Company); Xueying Wang, Center for Computational Biology and Bioinformatics, Indiana Univeristy School of Medicine; Pengyue Zhang, Center for Computational Biology and Bioinformatics, Indiana Univeristy School of Medicine; Kai Ding, University of Oklahoma Health Sciences Center; Lang Li, Center for Computational Biology and Bioinformatics, Indiana Univeristy School of Medicine; Wei Yue, University of Oklahoma Health Sciences Center
Physiologically Based Pharmacokinetic Modeling of the Drug Drug Interaction Between Rifampin and SGLT2 Inhibitors: The Contribution of CYP Induction to the Observed Interaction
Ernesto Callegari, Pfizer Inc.; Jian Lin, Pfizer Inc.; Susanna Tse, Pfizer Inc.; Theunis C. Goosen, Pfizer Inc.; Vaishali Sahasrabudhe, Pfizer Inc.; Vikas Kumar, Pfizer Inc.
Use of PBPK modeling for drug-drug interactions prediction of RIFAPENTINE on other drugs by induction of CYP3A4/5 and CYP2B6
Olivier Nicolas, sanofi; Helene Vermet, sanofi; Brigitte Demers, sanofi; Xavier Boulenc, sanofi; Eric Sultan, sanofi; François Donat, sanofi; Christine Farenc, sanofi
Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate
Katsuhiro Watanabe, Nagoya University Graduate School of Medicine; Shingo Oda, Nagoya University Graduate School of Medicine; Sho Akai, Nagoya University Graduate School of Medicine; Akiko Matsubara, Nagoya University Graduate School of Medicine; Tsuyoshi Yokoi, Nagoya University Graduate School of Medicine
FURTHER EXPLORATION INTO THE DRUG-DRUG INTERACTION BETWEEN GEMFIBROZIL AND REPAGLINIDE IN RATS: UPTAKE TRANSPORT
Chase I McCoy, Sekisui XenoTech, LLC; Forrest A Stanley, Sekisui XenoTech, LLC; Chandra Kollu, Sekisui XenoTech, LLC; Seema Muranjan, Sekisui XenoTech, LLC; Krystal M Green, Sekisui XenoTech, LLC; Joanna E Barbara, Sekisui XenoTech, LLC
Development of an in-vitro Method as a Tool to Assess UDP-Glucuronyltransferase (UGT) 2B10 Inhibition
Tim Creegan, Corning Incorporated, Life Sciences; Lisa Jacob, Corning Incorporated, Life Sciences; Ritu Singh, Corning Incorporated, Life Sciences; J. George Zhang, Corning Incorporated, Life Sciences
Evaluation of the Drug-Mediated Induction of Metabolic Enzymes Using a Novel CYP3A/PXR Humanized Mouse to Predict Intestinal Pharmacokinetics
Daisuke Satoh, Tottori University; Kaoru Kobayashi, Chiba University; Jiro Kuze, Taiho Pharmaceutical Co., Ltd.; Takushi Yamamoto, Shimadzu corporation; Katsuhide Igarashi, Hoshi University School of Pharmacy and Pharmaceutical Science; Satoshi Kitajima, Biological Safety Research Center, National Institute of Health Sciences; Jun Kanno, Biological Safety Research Center, National Institute of Health Sciences; Kan Chiba, Chiba University; Mitshuhiko Osaki, Tottori University; Mitsuo Oshimura, Tottori University; Kazuki Yasuhiro, Tottori University
ESTABLISHMENT OF IN SILICO PREDICTION MODELS FOR CYTOCHROME P450 INDUCTIONS IN HUMAN HEPATOCYTES USING AZOLE COMPOUNDS
Mika Nagai, Sch Pharm Sci, Univ Shizuoka; Kouichi Yoshinari, Sch Pharm Sci, Univ Shizuoka
Short- and Long-term Effects on Cytochrome P450 Expression and Induction Following Phenytoin Exposure at the Neonatal Age
Stephanie Piekos, University of Connecticut School of Pharmacy; Liming Chen, University of Connecticut School of Pharmacy; Xiaochao Ma, University of Pittsburgh; Pengcheng Wang, University of Pittsburgh; Xiao-bo Zhong, University of Connecticut School of Pharmacy
TRAC: A Novel Gene Expression Quantification Method - Compared to qPCR
Hinnerk Boriss, ValiFinn Ltd; Francesco Rossignolo, Aptuit; Stefano Fontana, Aptuit; Jani Salmivaara, Valfinn Ltd; Oona Kivela, Valfinn Ltd
CONSIDERATIONS FROM THE IQ INDUCTION WORKING GROUP IN RESPONSE TO DRUG-DRUG INTERACTION GUIDANCES FROM REGULATORY AGENCIES
Niresh Hariparsad, Vertex Pharmaceuticals, Inc.; Heidi Einolf, Novartis Institutes for BioMedical Research Inc.; Jane Kenny, Genentech Inc.; Diane Ramsden, Boehringer Ingelheim Pharmaceuticals Inc; David Buckley, XenoTech, LLC; Shannon Dallas, Janssen Research and Development.; Joshua Gordon DeKeyser, Amgen Inc.; Jairam Palamanda, Merck Research Laboratories; Conrad Fung, Vertex; Michael A Mohutsky, Eli Lilly and Company; George Zhang, Corning Incorporated, Life Sciences; Suresh Balani, Takeda Pharmaceuticals International Company; Liangfu Chen, GlaxoSmithKline; Barry Jones, Astrazeneca; Michael Sinz, Bristol Myers Squibb; Y. Amy Siu, Eisai Inc.; Robert Leonard Walsky, EMD Serono; Donald John Tweedie, Merck
EVALUATION OF POOLED HUMAN HEPATOCYTES TO ASSESS THE INDUCTION POTENTIAL OF NEW CHEMICAL ENTITIES
Jean Simmermacher, Bristol-Myers Squibb; Russell A Jarres, ThermoFisher; Lucien Tarabelsi, ThermoFisher; Wendy J Bray, ThermoFisher; Rafal P. Witek, ThermoFisher; Ramola Sane, Bristol-Myers Squibb; Michael Sinz, Bristol-Myers Squibb; Matthew Soars, Bristol-Myers Squibb
NADPH-independent inactivation of CYP2B6 by pyrrolobenzodiazepine dimer and potential impact on time-dependent inhibition assay of covalent inhibitors.
Mika Kosaka, Genentech, Inc.; Donglu Zhang, Genentech, Inc.; Jing Wang, Genentech, Inc.; Zhengyin Yan, Genentech, Inc.; Simon Wong, Genentech, Inc.
DETERMINING THE POTENCY OF INHIBITION OF FIVE GRAS OR DIETARY COMPOUNDS TO INHIBIT THE OXIDATIVE AND CONJUGATIVE METABOLISM OF BUPRENORPHINE
Neha V Maharao, Virginia Commonwealth University; Phillip M Gerk, Virginia Commonwealth Univ
Evaluation of Inhibitory Potential of SRD005825 on Human CYP Enzymes
Zhen Lou, Shire; Sara Leitz, Covance Laboratories Inc.; Devin Welty, Shire; Jody Wanta, Drug Metabolism and Disposition, Covance Laboratories Inc.; Daniel Albaugh, Covance Laboratories Inc.; Amy Nehmer, Covance Laboratories Inc.; Serene Josiah, Shire; Donald McKenzie, Covance Laboratories Inc.; Gang Luo, Covance Laboratories Inc.
XANTHINE OXIDASE: STRUCTURAL DIVERSITY OF INHIBITORS, STEATOTIC IMPLICATIONAND AGE-RELATED EXPRESSION
Ling Zhao, University of Rhode Island; Bo Yang, University of Rhode Island; Yuanjun Shen, University of Rhode Island; Zhen Xu, University of Rhode Island; Karen Ho, University of Rhode Island; Yi-Tzai Chen, University of Rhode Island; Bingfang Yan, University of Rhode Island
UGT1A8: ATYPICAL ENZYME KINETICS
Jennifer Byerley, Boehringer Ingelheim; Jin Zhou, Boehringer Ingelheim; Aaron Teitelbaum, Boehringer Ingelheim
Initiation of proliferation of primary differentiated liver cells
Astrid Noerenberg, upcyte technologies GmbH; Nils Runge, upcyte technologies GmbH; Torge Evenburg, upcyte technologies GmbH; Timo Johannssen, upcyte technologies GmbH
Regulation of UDP glucuronosyltransferase 2B genes in breast cancer cells
Robyn Meech, Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine; Dong Gui Hu, Department of Clinical Pharmacology, Flinders University; Apichaya Chanawong, Department of Clinical Pharmacology,Flinders University; Lu Lu, Department of Clinical Pharmacology, Flinders University; Nurul Mubarokah, Department of Clinical Pharmacology, Flinders University; Ross A. McKinnon, Flinders University, Centre for innovation in cancer; Peter I. Mackenzie, Department of Clinical Pharmacology and Centre for Innovation in Cancer, Flinders University
ROLE OF ORGANOCHLORINE PESTICIDE IN INITIATING ENDOTHELIAL DYSFUNCTION MEDIATED VIA CYTOCHROME P4501A1
Neeru Singh, University College of Medical Sciences (University of Delhi) and GTB Hospital, Department of Biochemistry; Manushi Siddarth, University College of Medical Sciences (University of Delhi) and GTB Hospital, Multidisciplinary Research Unit; Rishila Ghosh, University college of medical sciences, Delhi University,India; B. D. Banerjee, UCMS & GTB Hospital; Pawan KUMAR Kare, University college of medical sciences, Delhi University,India; Neelam Wadhwa, University college of medical sciences, Delhi University,India; Ashok KUMAR Tripathi, University college of medical sciences, Delhi University,India
TRANSCRIPTIONAL AND EPIGENETIC REGULATION OF METABOLIZING ENZYMES AND TRANSPORTER PROTEINS IN THE HUMAN INTESTINE AS CAUSED BY PROTOTYPICAL INDUCERS OF METABOLISM AND TRANSPORT
Susanne Brück, University Medicine of Greifswald; Diana Busch, University Medicine of Greifswald; Ingolf Cascorbi, University Hospital Schleswig-Holstein; Henrike Bruckmüller, University Hospital Schleswig-Holstein; Stefan Oswald, University Medicine of Greifswald
GLOBAL PROTEOMIC ANALYSIS OF TRANSPORTER PROTEINS IN THE HUMAN SMALL INTESTINE AND ESTABLISHED INTESTINAL CELL LINES
Janett Müller, University Medicine of Greifswald; Elke Hammer, University Medicine Greifswald; Manuela Gesell Salazar, University Medicine Greifswald; Anja Fritz, University Medicine of Greifswald; Lars Ivo Partecke, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, University Medicine of Greifswald; Claus-Dieter Heidecke, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, University Medicine of Greifswald; Uwe Völker, University Medicine Greifswald; Stefan Oswald, University Medicine of Greifswald
Label-Free Quantitation of Chorismate Biosynthesis Pathway Protein Expression in Yeast Following Treatment With Glyphosate
Christopher A Bolcato, Protea Biosciences; Jennifer A Gallagher, West Virginia University; Gregory Boyce, Protea Biosciences; Callee Walsh, Protea Biosciences; Matthew D Maust, Protea Biosciences; Sujatha Chilakala, Protea Biosciences
Using LC-MS Based Global Metabolomics of Formalin-Fixed, Paraffin-Embedded Tumor Tissue to Identify Potential Biomarkers
Gregory Boyce, Protea Biosciences; Callee Walsh, Protea Biosciences; Erin Seeley, Protea Biosciences; Sujatha Chilakala, Protea Biosciences
Use of SWATH-MS to relatively quantify the expression of hepatic drug metabolizing enzymes in human liver microsomes using a label-free approach
Rohitash Jamwal, University of Rhode Island; Benjamin J Barlock, University of Rhode Island; Sravani Adusumalli, University of Rhode Island; Ken Ogasawara, University of Rhode Island; Brigitte L Simons, SCIEX; Fatemeh Akhlaghi, University of Rhode Island
EFFECT OF ORAL TESTOSTERONE ON THE PLASMA STEROID METABOLOMICS IN HUMANS
Abdul Basit, University of Washington; Hay Young Zhang, University of Washington; Deepak Kumar Bhatt, University of Washington; John K Amory, University of Washington; Bhagwat Prasad, University of Washington
Comparative Pharmacoproteomics of Phenobarbital and CITCO in Human Primary Hepatocytes
Bryan Mackowiak, University of Maryland School of Pharmacy; Weiliang Huang, Pharmaceutical Sciences, University of Maryland School of Pharmacy; Zhihui Li, Pharmaceutical Sciences, University of Maryland School of Pharmacy; Maureen A Kane, Pharmaceutical Sciences, University of Maryland School of Pharmacy; Hongbing Wang, University of Maryland School of Pharmacy
Generation of expanded primary hepatocytes as a new tool for more predictive cell based screenings
Astrid Noerenberg, upcyte technologies GmbH; Nils Runge, upcyte technologies GmbH; Torge Evenburg, upcyte technologies GmbH; Timo Johannssen, upcyte technologies GmbH
Experimental conditions routinely used in human hepatocyte studies to improve the in vitro induction of CYP2D6 and CYP2C
Solenne Martin, EUROSAFE; Beatrice Lopez, EUROSAFE; Jenifer Carteret, EUROSAFE; Christophe Chesne, EUROSAFE
Use of a reliable metabolically competent human RGHep+ hepatocyte model engineered with biological tracers for In vitro micronucleus test associating high-content imaging
Vanessa Graillot, TOXALIM; Thibault Metenier, TOXALIM; Odile Mondesert, ITAV; Julien Vignard, TOXALIM; Valerie Lobjois, ITAV; Emmanuelle Bazin, EUROSAFE; Sandrine Camus, BIOPREDIC INTERNATIONAL; Christiane Guguen-Guillouzo, BIOPREDIC INTERNATIONAL; Ruoya LI, BIOPREDIC INTERNATIONAL; Christophe Chesne, BIOPREDIC INTERNATIONAL; Bernard Ducommun, TOXALIM; Bernard Salles, TOXALIM; Gladys Mirey, TOXALIM
Persistent hepatitis B virus infection in self-assembling microscale primary hepatocyte co-culture
Benjamin Y Winer, Princeton University; Amit Parekh, HµREL Corporation; Brigitte Heller, Princetone University; Gabriel Lipkowitz, Princeton University; Raymond Guo, Princeton University; Cheul Cho, HµREL Corporation; Anil Shrirao, HµREL Corporation; Eitan Pludwinski, HµREL Corporation; E. Novik, HµREL Corporation; Alexander Ploss, Princeton University
Genotoxicity of Heterocyclic Aromatic Amines using a new 3D Human Hepatic Model
Sophie Rose, UMR INSERM 1085 IRSET; Frédéric Ezan, UMR INSERM 1085 IRSET; Georges Baffet, UMR INSERM 1085 IRSET; Sophie Langouet, UMR INSERM 1085 IRSET
A HIGH-THROUGHPUT MICROFLUIDIC 3D HUMAN LIVER TISSUE MODEL FOR HEPATOTOXICITY PREDICTION
Anthony D Saleh, Mimetas; Paul Vulto, Mimetas BV; Albert Gough, University of Pittsburgh; D. Lansing Taylor, University of Pittsburgh
Age as a Factor in the Activation of Hepatic Xbox-Binding Protein 1 by the Anti-HIV Drug Efavirenz
Allyson Naugle Hamlin, Johns Hopkins Medical Institute; Carley J.S. Heck, Johns Hopkins University School of Medicine; Namandje N Bumpus, Johns Hopkins University School of Medicine
Validation of COCKTAIL ENZYME ASSAY IN 96-WELL PLATED HUMAN HEPATOCYTES FOR CYP1A2, CYP2B6 and CYP3A4 INDUCTION STUDIES WITH LC-MS/MS ANALYSIS
Kankika V Choughule, Corning Incorporated, Life Sciences; Thuy Ho, Corning Incorporated, Life Sciences; Duan Wang, Corning Incorporated, Life Sciences; David M. Stresser, Corning Incorporated, Life Sciences; Sarah K Trisdale, Corning Incorporated, Life Sciences; Tim Creegan, Corning Incorporated, Life Sciences; Ritu Singh, Corning Incorporated, Life Sciences; J. George Zhang, Corning Incorporated, Life Sciences
MetMax™ Pooled Donor Human Hepatocytes: A Novel In Vitro System for the Evaluation of Hepatic Drug Metabolism
David Ho, In Vitro ADMET Laboratories Inc.; Nick Ring, In Vitro ADMET Laboratories Inc.; Kirsten Amaral, In Vitro ADMET Laboratories Inc.; Albert P. Li, In Vitro ADMET Laboratories Inc.
Application of MetMax™ pooled donor human hepatocytes in a higher throughput assay for human hepatic metabolic stability screening
Karin D. Brown, Array BioPharma Inc.; Gary P. Hingorani, Array BioPharma Inc.; Albert P. Li, In Vitro ADMET Laboratories Inc.
Evaluation of Herb-Drug Interactions with MetMax™ Pooled Donor Human Enterocytes: Results with Twenty Eight Commonly used Herbal Supplements
Carol Loretz, In Vitro ADMET Laboratories Inc.; Albert P. Li, In Vitro ADMET Laboratories Inc.
Distribution of Per- and Polyfluoroalkyl Substances in Human Urine and Serum
Kayoko Kato, CDC; Akil A. Kalathil, ORISE; Antonia M. Calafat, CDC; Xiaoyun (Sherry) Ye, Centers for Disease Control and Prevention
Sensitive LC-MS/MS Method for Quantification of Vitamin B12 in Rat Serum: Application to Pharmacokinetic Study.
Raghupathi Reddy Aleti, Suven Life Sciences Ltd; Lakshmi Prasanna Rayapati, Suven Life Sciences Ltd; Prathyusha Chunduru, Suven Life Sciences Ltd; Raghava Choudary Palacharla, Suven Life Sciences Ltd; Devender Reddy Ajjala, Suven Life Sciences Ltd; Ramakrishna Nirogi, Suven Life Sciences Ltd
LC-MS/MS method for the simultaneous quantification of artemether, dihydroartemisinin and lumefantrine in rabbit plasma and its application to a PK study
Nagasurya Prakash Padala, Suven Life Sciences Ltd; Rajesh Kumar Boggavarapu, Suven Life Sciences Ltd; Praveen Kunduru, Suven Life Sciences Ltd; Raghava Choudary Palacharla, Suven Life Sciences Ltd; Devender Reddy Ajjala, Suven Life Sciences Ltd; Ramakrishna Nirogi, Suven Life Sciences Ltd
An improved quantum mechanical model of P450-mediated aromatic oxidation.
Rasmus Leth, Optibrium Ltd; Peter Hunt, Optibrium Ltd; Nicholas W Foster, Optibrium Ltd; Matthew D Segall, Optibrium Ltd
DEVELOPING A MECHANISTIC ABSORPTION MODEL TO PREDICT THE PHARMACOKINETICS OF IMMEDIATE-RELEASE WEAK BASE DRUGS WITH A LONG TMAX BY INCORPORATING LYSOSOMAL TRAPPING
Jia Li, Office of Clinical Pharmacology, CDER, FDA; Zhongqi Dong, Office of Clinical Pharmacology, CDER, FDA; Fang Wu, Office of Pharmaceutical Quality, CDER, FDA; Ping Zhao, Office of Clinical Pharmacology, CDER, FDA; Sue Chih Lee, Office of Clinical Pharmacology, CDER, FDA; Paul Seo, Office of Pharmaceutical Quality, CDER, FDA; Lei Zhang, Office of Clinical Pharmacology, CDER, FDA
Augmenting decision making in early discovery – Efforts to derisk BSEP inhibition potential utilizing in silico modeling
Elizabeth Joshi, Merck Research Laboratories; Michael Hafey, Merck Research Laboratories; Robert Houle, Merck Research Laboratories; Prabha Karnachi, Merck Research Laboratories
Comparing Mechanistic and Pre-clinical Predictions of Volume of Distribution on a Large Set of Drugs
Rosa Chang, University of California; Tom De Bruyn, Genentech Inc; Matthew Wright, Genentech Inc; Fabio Broccatelli, Genentech Inc
EVALUATION OF SUNITINIB RELATED DRUG-DRUG INTERACTONS USING A FULL PHYSIOLOGICAL BASED PHARMACOKINETIC MODEL
Ganessan Kichenadasse, Flinders University; Andrew Rowland, Department of Clinical Pharmacology, Flinders University School of Medicine
Immunogenicity Risk Assessment Using Pre-clinical Tools For Biotherapeutics
Pu Shi, Takeda Pharmaceuticals International Co.; Christopher Gemski, Takeda Pharmaceuticals International Co.; Li Zhou, Takeda Pharmaceuticals International Co.; Jing-Tao Wu, Takeda Pharmaceuticals International Co.; Cindy Xia, Takeda Pharmaceuticals International Co.
Lack of estrogenic and anti-estrogenic activity of aromatic amines and their hydroxylated and acetylated metabolites on human breast cancer cells
Linh Chi Bui, CNRS UMR 8251, Université Paris Diderot, Sorbonne Paris Cité; Kevin Cariou, CNRS UPR 2301; Gautier Moroy, Inserm UMR-S 973, Université Paris Diderot, Sorbonne Paris Cité; Jean-Marie Dupret, CNRS UMR 8251, Université Paris Diderot, Sorbonne Paris Cité; Fernando Rodrigues-Lima, CNRS UMR 8251, Université Paris Diderot, Sorbonne Paris Cité
Efficient Generation of Human and Cynomolgus Monkey Induced Pluripotent Stem Cell-Derived Intestinal Organoids with Pharmacokinetic Functions
Daichi Onozato, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Misaki Yamashita, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Anna Nakanishi, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Takumi Akagawa, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Yuriko Kida, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Akiko Koeda, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Takahiro Iwao, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Tamihide Matsunaga, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University
Expanded primary cells for cell-based screenings
Astrid Noerenberg, upcyte technologies GmbH; Nils Runge, upcyte technologies GmbH; Torge Evenburg, upcyte technologies GmbH; Timo Johannssen, upcyte technologies GmbH
Determining the mechanisms behind distribution variability in small molecule pharmaceuticals using 3D spheroid tissues
David Mertz, University of Michigan; Siwei Li, University of Michigan; Kathy Luker, University of Michigan; Gary Luker, University of Michigan; Duxin Sun, University of Michigan; Shuichi Takayama, University of Michigan
Untargeted analysis of protein modification by drug-related chemicals using background subtraction and proteomic approach
Ming Yao, Bristol-Myers Squibb Co; Haiying Zhang, Bristol-Myers Squibb Co; Jinping Gan, Bristol-Myers Squibb; William G. Humphreys, Bristol-Myers Squibb
TOTAL HEPATOCELLULAR DISPOSITION PROFILING OF ACETAMINOPHEN AND MAJOR METABOLITES IN SANDWICH-CULTURED PXB-CELLS
Katsuhiro Kanda, Hitachi High-Technologies Corporation; Shinya Ito, Hitachi High-Technologies Corporation; Masuyuki Sugiyama, Hitachi Ltd.
Establishment of cholestatic drug-induced liver injury evaluation system in vitro using sandwich cultured human iPS cell-derived hepatocytes.
Yoko Sakai, Aichi Gakuin University; Takahiro Iwao, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Takeshi Susukida, The Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University; Akinori Takemura, The Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University; Takumi Nukaga, The Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University; Shuichi Sekine, Graduate School of Pharmaceutical Sciences, Chiba University; Kousei Ito, Graduate School of Pharmaceutical Sciences, Chiba University; Tamihide Matsunaga, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University
A Rapid Cocktail LC-MS/MS Method to Assess Inhibitor Selectivity for CYP Phenotyping in Human Liver Microsomes and Hepatocytes
Jeffrey M. Weber, Q2 Solutions; Brian Staton, Q2 Solutions; Lori Bunkowfst, Q2 Solutions; J. Matthew Hutzler, Q2 Solutions
DEVELOPMENT OF A PRIMARY HUMAN HEPATOCYTE SPHEROID CULTURE MODEL FOR DRUG METABOLISM AND DISPOSITION STUDIES
Kajsa P Kanebratt, AstraZeneca R&D Gothenburg; Annika Janefeldt, AstraZeneca R&D Gothenburg; Alexandra Peric, AstraZeneca R&D Gothenburg; Julia Jonsson, AstraZeneca R&D Gothenburg; Linnea Johansson, AstraZeneca R&D Gothenburg; Constanze Hilgendorf, AstraZeneca R&D Gothenburg; Tommy B Andersson, AstraZeneca R&D Gothenburg
In Vitro Investigation of Catabolism and Metabolism of Antibody Drug Conjugates (ADCs) 
Mithat Gunduz, Novartis Institutes for Biomedical Research Inc.; Amanda L Cirello, Tarveda Therapeutics; Jennifer L Dumouchel, Novartis Institutes for Biomedical Research Inc.; Dominik Hainzl, Novartis Institutes for Biomedical Research Inc.; Tony D’Alessio, Novartis Institutes for Biomedical Research Inc.; Carl Bialucha, Novartis Institutes for Biomedical Research Inc.; Vladimir Capka, Novartis Institutes for Biomedical Research Inc.; Upendra A Argikar, Novartis Institutes for Biomedical Research Inc.
Alginate-encapsulated primary human hepatocyte culture system to increase the accuracy of the predicted in vivo half-life of low clearance compounds
Miyoung Yoon, ScitoVation, LLC; Martin B Phillips, ScitoVation, LLC; Jeffrey R Enders, ScitoVation, LLC; Pergentino Balbuena-Venancio, ScitoVation, LLC; David Billings, ScitoVation, LLC; Rachel Norini, ScitoVation, LLC; Ruby Karsten, ScitoVation, LLC; Harvey J Clewell III, ScitoVation, LLC
High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models
Marianne Vormann, Mimetas; Linda Gijzen, Mimetas; Toni Steiner, MilliporeSigma; Dave Thompson, MilliporeSigma; Devon Anderson, MilliporeSigma; Anthony D Saleh, Mimetas; Jos Joore, Mimetas; Paul Vulto, Mimetas; Henriëtte Lanz, Mimetas
Impact of drugs increasing mRNA expressions of renal endocytic receptors on cadmium-induced nephrotoxicity
Keiko Hosohata, Osaka University of Pharmaceutical Sciences; Nathan Mise, Jichi Medical University; Sahoko Ichihara, Jichi Medical University; Kazunori Iwanaga, Osaka University of Pharmaceutical Sciences
CADMIUM-INDUCED ROS-MEDIATED KIDNEY FIBROSIS BY ACTIVATING TRANSFORMING GROWTH FACTOR-β PATHWAY IN HUMAN PROXIMAL TUBULAR EPITHELIAL CELLS
Manushi Siddarth, University College of Medical Sciences (University of Delhi) and GTB Hospital, Multidisciplinary Research Unit; Diwesh Chawla, University College of Medical Sciences (University of Delhi) and GTB Hospital, Multidisciplinary Research Unit; Neeru Singh, University College of Medical Sciences (University of Delhi) and GTB Hospital, Department of Biochemistry; Alpana Raizada, University College of Medical Sciences (University of Delhi) and GTB Hospital, Department of Medicine; Basu Dev Banerjee, University College of Medical Sciences (University of Delhi) and GTB Hospital, Department of Biochemistry; Meera Sikka, University College of Medical Sciences (University of Delhi) and GTB Hospital, Multidisciplinary Research Unit
UTILISATION OF 2D AND 3D HUMAN HEPATOCYTE APPROACHES TO DETECT AND PREDICT THE MITOCHONDRIAL TOXICITY OF CLINICAL FAILURES DUE TO DILI - A CASE STUDY WITH FASIGLISAM
Derek Angus, Cyprotex; Clive Dilworth, Cyprotex; Caroline Bauch, Cyprotex; Julie Eakins, Cyprotex; Paul Walker, Cyprotex
Bioactivation of 6-fluoro-1H-indazole to quinone methide intermediate: Oxidative defluorination via an arene oxide formation
Steve Bowlin, Takeda; Kirk Kozminski, Takeda; Shane Alexis Apostol, Takeda; Amin Kamel, Takeda
A New Mechanism-Based Human In Vitro Screen (C-DILI™ Assay) for Prediction of Cholestatic Liver Toxicity
Jonathan P. Jackson, Qualyst Transporter Solutions; Kimberly M Freeman, Qualyst Transporter Solutions; Robert L. St. Claire III, Qualyst Transporter Solutions; Matthew K Palmer, Qualyst Transporter Solutions; Christopher B Black, Qualyst Transporter Solutions; Kenneth R Brouwer, Qualyst Transporter Solutions
Effect of high mercury fish consumption on Emotional Intelligence
Neil Nedley, Nedley Clinic; Francisco E. Ramirez, Nedley Clinic
A STRUCTURAL ACTIVITY RELATIONSHIP STRATEGY TO MITIGATE CHOLESTATIC HEPATOXICITY LIABILITIES UTILIZING THE C-DILI™ ASSAY
Jonathan P. Jackson, Qualyst Transporter Solutions; Kimberly M. Freeman, Qualyst Transporter Solutions; Matthew K. Palmer, Qualyst Transporter Solutions; Robert L. St. Claire III, Qualyst Transporter Solutions; Christopher B Black, Qualyst Transporter Solutions; Kenneth R. Brouwer, Qualyst Transporter Solutions
See more of: General Abstracts